Clinical Trials Logo

Filter by:
NCT ID: NCT04493099 Withdrawn - Clinical trials for Refractory Acute Myeloid Leukemia

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Start date: October 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial investigates the side effects and best dose of alvocidib when given together with decitabine and venetoclax and to see how well it works in treating patients with acute myeloid leukemia that has come back (relapsed), has not responded to previous treatment (refractory), or as frontline treatment for patients unable to receive other therapies (unfit). Alvocidib, decitabine, and venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT04492059 Withdrawn - Clinical trials for Achilles Tendon Rupture

Use of Blood Flow Restriction Therapy in Perioperative Rehabilitation Following Achilles Tendon Rupture

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effect of utilizing blood flow restriction (BFR) therapy in the rehabilitation of Achilles tendon rupture (ATR). Muscle atrophy occurs following Achilles tendon rupture, whether managed non operatively or operatively, which has implications on patient outcomes. The goal of physical therapy in the perioperative period is to regain and ultimately return to activity. BFR has been proposed to reduce atrophy and maintain strength, which would theoretically mitigate the deconditioning effects of an injury on surrounding musculature. BFR is proposed to work by restricting arterial inflow leading to an oxygen depleted environment and the ability to induce muscle adaption at lower maximum repetition via reactive hyperemia and induction of growth cytokines, thus leading to muscle hypertrophy. The goal of this investigation is to determine if using BFR as an adjunct in physical therapy following ATR would reduce muscular atrophy and lead to increased and expedited strength gains. Additionally, the investigators would like to determine if BFR accelerates the rehabilitation process and allows patients to perform standard rehabilitative functional tests and return to play sooner. Furthermore, the investigators will investigate patient reported outcomes metrics. The investigators hypothesize that the BFR group will have significantly greater strength gains at all time points in both non operatively and operatively treated ATR. Previous studies have shown that BFR has potential in increasing Achilles tendon stiffness, tendon cross-sectional area, muscle strength and muscle hypertrophy. However, there is a lack of evidence regarding the use of BFR in both the pre and postoperative period specifically relating to ATR. The investigators believe that the use of BFR in the perioperative period surrounding an Achilles tendon rupture and ATR has the potential to significantly decreased muscle atrophy, improve patient satisfaction and lead to earlier return to sport.

NCT ID: NCT04489667 Withdrawn - HIV/AIDS Clinical Trials

HIV + Service Delivery and Telemedicine Through Effective PROs

HIV+STEP
Start date: March 19, 2021
Phase: N/A
Study type: Interventional

This study will examine the impact of using a multicomponent intervention (patient reported outcomes, training, and telemedicine) to assist with the management of Mental Health (MH) and Substance Use Disorders (SUD) among people living with HIV (PLWH) engaged in care at UAB HIV Clinic, University of Alabama Family Clinic (Birmingham, AL), Thrive Federally Qualified Health Services Center (Huntsville), Health Services Center (Anniston), and Medical Advocacy and Outreach (Montgomery). The study will employ a hybrid type 2 implementation design. Because this intervention will be employed as the new standard of care at participating sites, all PLWH receiving care at the sites will receive this intervention. Patient-reported outcomes (PROs) will be integrated into routine care to screen PLWH for substance use and mental health disorders during routine clinical encounters. Training will be delivered to frontline clinicians so that they receive targeted knowledge on best practices for treatment of MH and SUD along with clinic-specific protocols for response to PROs on MH and SUD including treatment and referrals. Telemedicine services for MH and SUD will be offered to patients in need of expanded access to services due to a lack of clinic-level resources or additional barriers to traditional clinic visits such transportation, stigma, or substance using behaviors.

NCT ID: NCT04489628 Withdrawn - SARS-CoV Infection Clinical Trials

Tele-health Enabled Clinical Trial for COVID-19

Start date: August 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the efficacy of high dose Vitamin D (an over-the-counter nutritional supplement) in preventing immune-related complications in outpatients with confirmed SARS-CoV-2 infection.

NCT ID: NCT04486846 Withdrawn - Prostate Cancer Clinical Trials

Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth)

Start date: June 2021
Phase: N/A
Study type: Interventional

The purpose of this single institution pilot study is to determine the feasibility of implementing an eHealth prostate cancer surveillance program through the eVisit electronic medical record patient portal. The investigators will assess patient compliance and satisfaction with eVisit follow up care in lieu of in person clinic visits.

NCT ID: NCT04483414 Withdrawn - Prostate Cancer Clinical Trials

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

Start date: March 19, 2021
Phase: Phase 2
Study type: Interventional

The goal of this research is to examine the ability of Gallium-68 (68Ga) Prostate-Specific Membrane Antigen-11 (PSMA-11) positron emission tomography/computed tomography (PET/CT) to detect sites of recurrent prostate cancer in patients with biochemical recurrence previously treated with radical prostatectomy (RP) or external beam radiation (EBRT) and to assess treatment response to subsequent salvage therapy.

NCT ID: NCT04482712 Withdrawn - Respiratory Failure Clinical Trials

Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS

RAPA-CARDS
Start date: April 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study assesses the clinical effectiveness of mammalian target of rapamycin (mTOR) inhibition with rapamycin in minimizing or decreasing the severity of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in participants infected with mild to moderate COVID-19 virus.

NCT ID: NCT04480411 Withdrawn - Covid19 Clinical Trials

Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients

Start date: January 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the use of technology including remote vital sign monitoring in improving quality of patient care, decreasing hospital admissions and re-admissions, decreasing hospital length of stay and decreasing use of personal protective equipment.

NCT ID: NCT04480190 Withdrawn - Cholangiocarcinoma Clinical Trials

Neoadjuvant Therapy in Biliary Adenocarcinoma

Start date: February 4, 2021
Phase: Phase 1
Study type: Interventional

Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.

NCT ID: NCT04477642 Withdrawn - COVID-19 Clinical Trials

Abatacept for Patients With COVID-19 and Respiratory Distress

Start date: August 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm open label trial for hospitalized patients with COVID-19 (Coronavirus). The primary endpoint of the study is to assess the requirement for mechanical ventilation in patients who are admitted to the hospital with COVID-19 infection and a Pulse Oxygen Level </= 93% on room air. The primary endpoint analysis will be performed using all enrolled patients.